A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
Terminated · Phase 1 · NCT06119529
Conditions: Healthy, Atopic Dermatitis
At a glance
- Research payments reported, 2025
- $15,468
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 18
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY3872386 (drug), Prednisone (drug), Placebo (drug)
- Dates
- Started 2023-11-01; completion 2024-04-08
- Results posted
- Yes
The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants. Blood tests will be performed to investigate how the body processes the LY3872386 following single and multiple dosing in healthy participants and participants with atopic dermatitis. Blood tests will also be performed to investigate how the body processes the prednisone in healthy participants. The study is conducted in three parts (part A, B and C). The study will last up to approximately 85, 183 and 44 days for parts A, B, and C, respectively.
From ClinicalTrials.gov, last updated 2025-10-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $15,468 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research Unit Inc $15,468
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.